Peptide Initiative
Back to Thymosin Beta-4

Clinical trials

Every registered trial of Thymosin Beta-4

12 studies, 2 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Very little human research on Thymosin Beta-4 has been registered.
  • 12 registered studies in total.
  • 2 are still enrolling people, so this is active research, not just history.

What kind of research

  • 12 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 2,004 people took part in those.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 12 of 12 trials for Thymosin Beta-4.

  • NCT07487363 Phase 1/2Recruiting80 enrolled2026

    TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

    Hudson Biotech

    Atherosclerotic Cardiovascular Diseases · Endothelial Dysfunction

  • 2024-518969-98-00 Revoked35 enrolled2025

    RGN-NK-302

    Regentree LLC

    Neurotrophic Keratopathy

  • 2022-502697-16-00 Revoked70 enrolled2023

    SEER-3

    Regentree LLC

    Neurotrophic Keratopathy

  • NCT05555589 Phase 3Recruiting70 enrolled2023

    Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

    ReGenTree, LLC

    Neurotrophic Keratopathy

  • NCT03937882 Phase 3Completed700 enrolled2019

    Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

    ReGenTree, LLC

    Dry Eye Syndromes · Dry Eye

  • NCT02974907 Phase 3Completed601 enrolled2016

    Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

    ReGenTree, LLC

    Dry Eye Syndrome

  • NCT02600429 Phase 3Terminated18 enrolled2015

    Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

    ReGenTree, LLC

    Neurotrophic Keratopathy

  • NCT02597803 Phase 2/3Completed317 enrolled2015

    Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

    ReGenTree, LLC

    Dry Eye Syndrome

  • NCT02668055 Phase 1Completed20 enrolled2012

    Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds

    Chinese PLA General Hospital

    Wounds

  • NCT01387347 Phase 2Completed72 enrolled2011

    Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

    ReGenTree, LLC

    Dry Eye Syndrome · Dry Eye

  • NCT01393132 Phase 2Completed9 enrolled2011

    Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

    Michigan Cornea Consultants, PC

    Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT00598871 Phase 2Terminated12 enrolled2007

    A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

    ReGenTree, LLC

    Diabetes

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Thymosin Beta-4 is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.